Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carolyn D Britten

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Molecular Cancer Therapeutics|October 16, 2004
Targeting ErbB receptor signaling: a pan-ErbB approach to cancerCarolyn D Britten
Cancer Chemotherapy and Pharmacology|February 28, 2013
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor typesCarolyn D Britten
Hematology/Oncology Clinics of North America|January 7, 2003
Clinical trial designs for targeted agentsBrigette B Y Ma, Carolyn D Britten, Lillian L Siu
The Journal of Pharmacology and Experimental Therapeutics|June 4, 2016
Redox Signaling and Bioenergetics Influence Lung Cancer Cell Line Sensitivity to the Isoflavone ME-344Yefim Manevich, Leticia Reyes, Carolyn D Britten, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 17, 2008
Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse modelRichard S Finn, Greg Bentley, Carolyn D Britten, et al.
American Journal of Clinical Oncology|July 18, 2022
Clinical Significance of Transient Asymptomatic Elevations in Aminotransferase (TAEAT) in OncologyJames H Lewis, Sophia K Khaldoyanidi, Carolyn D Britten, et al.
International Journal of Medical Informatics|August 25, 2019
Automatic trial eligibility surveillance based on unstructured clinical dataStéphane M Meystre, Paul M Heider, Youngjun Kim, et al.
Cancer Chemotherapy and Pharmacology|May 17, 2007
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off periodCarolyn D Britten, Fairooz Kabbinavar, J Randolph Hecht, et al.
Cancer Chemotherapy and Pharmacology|September 7, 2007
Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safetyFeng Guo, Stephen P Letrent, Pamela N Munster, et al.
Cancer Chemotherapy and Pharmacology|September 7, 2014
The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumorsSunil Sharma, Carolyn D Britten, Joanne Mortimer, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Molecular Cancer Therapeutics|October 16, 2004
Targeting ErbB receptor signaling: a pan-ErbB approach to cancerCarolyn D Britten
Cancer Chemotherapy and Pharmacology|February 28, 2013
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor typesCarolyn D Britten
Hematology/Oncology Clinics of North America|January 7, 2003
Clinical trial designs for targeted agentsBrigette B Y Ma, Carolyn D Britten, Lillian L Siu
The Journal of Pharmacology and Experimental Therapeutics|June 4, 2016
Redox Signaling and Bioenergetics Influence Lung Cancer Cell Line Sensitivity to the Isoflavone ME-344Yefim Manevich, Leticia Reyes, Carolyn D Britten, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 17, 2008
Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse modelRichard S Finn, Greg Bentley, Carolyn D Britten, et al.
American Journal of Clinical Oncology|July 18, 2022
Clinical Significance of Transient Asymptomatic Elevations in Aminotransferase (TAEAT) in OncologyJames H Lewis, Sophia K Khaldoyanidi, Carolyn D Britten, et al.
International Journal of Medical Informatics|August 25, 2019
Automatic trial eligibility surveillance based on unstructured clinical dataStéphane M Meystre, Paul M Heider, Youngjun Kim, et al.
Cancer Chemotherapy and Pharmacology|May 17, 2007
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off periodCarolyn D Britten, Fairooz Kabbinavar, J Randolph Hecht, et al.
Cancer Chemotherapy and Pharmacology|September 7, 2007
Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safetyFeng Guo, Stephen P Letrent, Pamela N Munster, et al.
Cancer Chemotherapy and Pharmacology|September 7, 2014
The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumorsSunil Sharma, Carolyn D Britten, Joanne Mortimer, et al.
Pageof 4